- Home
- SRTAW vs BLRX Comparison
SRTAW vs BLRX Comparison
Compare SRTAW & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTAW
- BLRX
- Stock Information
- Founded
- SRTAW N/A
- BLRX 2003
- Country
- SRTAW United States
- BLRX Israel
- Employees
- SRTAW N/A
- BLRX N/A
- Industry
- SRTAW
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SRTAW
- BLRX Health Care
- Exchange
- SRTAW Nasdaq
- BLRX Nasdaq
- Market Cap
- SRTAW 16.3M
- BLRX 17.0M
- IPO Year
- SRTAW 2019
- BLRX 2011
- Fundamental
- Price
- SRTAW $0.15
- BLRX $3.67
- Analyst Decision
- SRTAW
- BLRX Strong Buy
- Analyst Count
- SRTAW 0
- BLRX 2
- Target Price
- SRTAW N/A
- BLRX $19.00
- AVG Volume (30 Days)
- SRTAW N/A
- BLRX 32.7K
- Earning Date
- SRTAW N/A
- BLRX 08-14-2025
- Dividend Yield
- SRTAW N/A
- BLRX N/A
- EPS Growth
- SRTAW N/A
- BLRX N/A
- EPS
- SRTAW N/A
- BLRX N/A
- Revenue
- SRTAW N/A
- BLRX $17,251,000.00
- Revenue This Year
- SRTAW N/A
- BLRX N/A
- Revenue Next Year
- SRTAW N/A
- BLRX N/A
- P/E Ratio
- SRTAW N/A
- BLRX N/A
- Revenue Growth
- SRTAW N/A
- BLRX 1.19
- 52 Week Low
- SRTAW N/A
- BLRX $2.30
- 52 Week High
- SRTAW N/A
- BLRX $26.80
- Technical
- Relative Strength Index (RSI)
- SRTAW N/A
- BLRX 44.89
- Support Level
- SRTAW N/A
- BLRX $3.42
- Resistance Level
- SRTAW N/A
- BLRX $3.79
- Average True Range (ATR)
- SRTAW 0.00
- BLRX 0.25
- MACD
- SRTAW 0.00
- BLRX 0.02
- Stochastic Oscillator
- SRTAW 0.00
- BLRX 47.17
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.